Original Publication Date: 1 November, 2016
Publication / Source: Future Oncology
Authors: Jamie N Holtz, Kae Jack Tay, Thomas J Polascik & Rajan T Gupta
Prostate cancer is the most common noncutaneous cancer in men though many men will not die of this disease and may not require definitive treatment. Active surveillance (AS) is an increasingly utilized potential solution to the issue of overtreatment of prostate cancer. Traditionally, prostate cancer patients have been stratified into risk groups based on clinical stage on digital rectal examination, prostate-specific antigen and biopsy Gleason score, though each of these variables has significant limitations.